Efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for hepatitis C in Korea: a Phase 3b study
Jeong Heo, Yoon Jun Kim, Sung Wook Lee, Youn-Jae Lee, Ki Tae Yoon, Kwan Soo Byun, Yong Jin Jung, Won Young Tak, Sook-Hyang Jeong, Kyung Min Kwon, Vithika Suri, Peiwen Wu, Byoung Kuk Jang, Byung Seok Lee, Ju-Yeon Cho, Jeong Won Jang, Soo Hyun Yang, Seung Woon Paik, Hyung Joon Kim, Jung Hyun Kwon, Neung Hwa Park, Ju Hyun Kim, In Hee Kim, Sang Hoon Ahn, Young-Suk Lim
Korean J Intern Med. 2023;38(4):504-513. Published online 2023 Jun 30 DOI: https://doi.org/10.3904/kjim.2022.252
Citations to this article as recorded by 
Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection
Hyun Phil Shin
The Korean Journal of Internal Medicine.2023; 38(4): 454. CrossRef
Sofosbuvir and Velpatasvir Regimen Outcome for Chronic Hepatitis C Patients With End-Stage Renal Disease Undergoing Hemodialysis
Salman Shahid, Shoaib Asghar, Tayyab Mahmood, Mishal Fatima, Ali Rasheed, Sohaib Asghar
Cureus.2023;[Epub] CrossRef